KIA
CRL icon

Knollwood Investment Advisory’s Charles River Laboratories CRL Stock Holding History

Knollwood Investment Advisory’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+994
New +$177K 0.02% 256
2024
Q3 		– Sell
-994
Closed -$205K – 358
2024
Q2 		$205K Buy
+994
New +$225K 0.02% 348

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Knollwood Investment Advisory's CRL Position: Q2 2026 in Review

Knollwood Investment Advisory opened a new position in Charles River Laboratories (CRL) in Q2 2026: 994 shares worth $225K. The stake represents 0.02% of the portfolio and ranks #256 among its holdings. This is a return to the name: Knollwood Investment Advisory previously reported a position in CRL as recently as Q2 2024.

Knollwood Investment Advisory first reported a position in CRL in Q2 2024 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Knollwood Investment Advisory held 994 shares of Charles River Laboratories worth $225K as of Q2 2026.
  • Charles River Laboratories was a new Knollwood Investment Advisory position in Q2 2026.
  • Charles River Laboratories made up 0.02% of Knollwood Investment Advisory's portfolio in Q2 2026, its #256 holding.
  • Knollwood Investment Advisory first reported a position in Charles River Laboratories in Q2 2024 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Knollwood Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.